Home › Companies › NTLA

Intellia Therapeutics

Market cap $1.37B 140.4M shares (10-Q, Oct 30, 2026) × $9.78 close Nov 17, 2026

Most recent annual filing: 2026-02-15

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. MAGNITUDE ATTR-CM corporate update2H 2026 / early 2027MAGNITUDE ATTR-CM corporate update, 2H 2026 / early 2027, notable
  2. lonvo-z commercial launch1H 2027lonvo-z commercial launch, 1H 2027, routine
  3. lonvo-z HAE PDUFA dateMar 10, 2027lonvo-z HAE PDUFA date, Mar 10, 2027, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (3 active programs)

Capital (as filed)

Cash
$156M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$318M Sep 30, 2026
Long-term investments
$141M Sep 30, 2026
Operating cash flow
−$85.4M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$615M cash, runway at least into 2028 per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (11)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (11 calls)

Every verdict Biotech Distilled has published on Intellia Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Intellia Therapeutics (NTLA) - Scientific Deep Dive for Lead and Pipeline Products Brilliant first-in-class CRISPR science is burdened by an active FDA clinical hold on the ATTR-CM program and a contested IP landscape, making entry premature.
  2. Watch UPDATE: Intellia Therapeutics (NTLA) - The Clock Is Set for Monday Morning Maintaining Watch List stance ahead of the binary HAELO Phase 3 readout; advising existing holders to hold and non-holders to avoid chasing the print.
  3. Buy core UPDATE: Intellia Therapeutics (NTLA) - The Code Compiled Clean HAELO Phase 3 hit primary endpoint with 87% attack reduction and zero SAEs, retiring clinical risk on lonvo-z and initiating a rolling BLA; buy the offering price once it prices, not the print.
  4. Buy core UPDATE: Intellia Therapeutics (NTLA) - The Offering Priced at $10.75 Offering priced at $10.75 sets the entry; lonvo-z BLA on the clock with runway extended to 2028, while platform remains on hold pending MAGNITUDE resolution.
  5. Speculative buy speculative UPDATE: Intellia Therapeutics (NTLA) - The MAGNITUDE Hold Quietly Lifted FDA lifting the MAGNITUDE ATTR-CM clinical hold closes the single largest gap in the bull thesis, justifying an upgrade from platform HOLD to Speculative Buy on the full platform, though IP risks and unresolved safety questions remain.
  6. Speculative buy speculative UPDATE: Intellia Therapeutics (NTLA) - The HAELO Receipts Land in NEJM Full HAELO dataset published in NEJM confirms all secondary endpoints with margin, reinforcing the lonvo-z BLA narrative; platform speculative buy maintained as MAGNITUDE safety data remains the next true binary.
  7. Speculative buy speculative UPDATE: Intellia Therapeutics (NTLA) - They Found the Bug Retrospective HLA allele association provides a mechanistic, screenable explanation for nex-z hepatotoxicity, de-risking but not resolving the platform safety question; speculative buy maintained with the stock 25% lower than the June update.
  8. Speculative buy speculative UPDATE: Intellia Therapeutics (NTLA) - They Mortgaged the Codebase Non-dilutive $400M OrbiMed debt facility funds the launch without new equity issuance, but pledging contested IP as first-lien collateral changes the risk composition; speculative buy maintained.
  9. Speculative buy speculative UPDATE: Intellia Therapeutics (NTLA) - The Clock Has a Date on It Now FDA accepted the lonvo-z BLA with priority review and set a March 10, 2027 PDUFA date, converting an open-ended regulatory wait into a six-month countdown and unlocking the OrbiMed approval tranche.
  10. Speculative buy speculative UPDATE: Intellia Therapeutics (NTLA) - No Panel, and a Sell-Off Anyway FDA confirmed no advisory committee planned for lonvo-z, MAGNITUDE-2 fully enrolled, and launch narrowed to Q1 2027; speculative buy maintained as the regulatory path is cleaner despite the stock selling off.
  11. Speculative buy speculative UPDATE: Intellia Therapeutics (NTLA) - Four Years, No Crack Phase 1/2 data show lonvo-z kallikrein knockdown maintained for up to four years with no waning, answering the durability question ahead of the March 10 PDUFA; speculative buy maintained with the stock cheaper than at prior updates.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (5 quotes from 5 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (37)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 5, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

6 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)